Suchetha S, Vijayashanti T, Rema P, Sivaranjith J, Kumar Aswin, Krishna K M Jagathnath, James Francis V
Division of Gynaecologic Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
Division of Surgical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.
J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):306-312. doi: 10.1007/s13224-021-01612-9. Epub 2022 Feb 23.
Uterine sarcomas are heterogeneous group of tumours comprising 1% of gynaecological malignancies. There is lack of concences on optimal treatment of uterine sarcomas. This is because of lack of randomised controlled trials due to rarity of these tumours. Surgical management without spill remains the standard primary treatment. Most of the times uterine sarcomas are diagnosed postoperatively from histopathology report of either myomectomy or hysterectomy. This retrospective study analysed the clinico pathological characteristics, prognostic factors, treatment details and survival outcome of different types of uterine sarcomas.
This is a retrospective analysis of 59 patients of uterine sarcomas. All patients underwent surgery. Adjuvant chemotherapy or radiation treatment were given according to histopathological report and FIGO stage. Patients were followed up every three months for first two years and then every six months. Disease free survival (DFS) and Overall survival (OS) were calculated.
The data were summarized using descriptive statistics as mean, percent and range. Survival probabilities were estimated using Kaplan-Meier method and the significance of difference between the survival curves were calculate using log-rank test.
Uterine sarcomas are rare and aggressive tumours of uterus. Majority of these tumours present in early stage. Surgery remains the main treatment modality. Role of adjuvant radiation treatment remains controversial. Tumour stage is the most important prognostic factor.
子宫肉瘤是一组异质性肿瘤,占妇科恶性肿瘤的1%。对于子宫肉瘤的最佳治疗方法尚无共识。这是因为这些肿瘤罕见,缺乏随机对照试验。无瘤手术仍然是标准的主要治疗方法。大多数情况下,子宫肉瘤是在肌层切除术或子宫切除术后根据组织病理学报告确诊的。这项回顾性研究分析了不同类型子宫肉瘤的临床病理特征、预后因素、治疗细节和生存结果。
这是一项对59例子宫肉瘤患者的回顾性分析。所有患者均接受了手术。根据组织病理学报告和国际妇产科联盟(FIGO)分期给予辅助化疗或放疗。患者在头两年每三个月随访一次,之后每六个月随访一次。计算无病生存期(DFS)和总生存期(OS)。
数据采用描述性统计方法进行汇总,以均值、百分比和范围表示。使用Kaplan-Meier方法估计生存概率,并使用对数秩检验计算生存曲线之间差异的显著性。
子宫肉瘤是子宫罕见且侵袭性强的肿瘤。这些肿瘤大多在早期出现。手术仍然是主要的治疗方式。辅助放疗的作用仍存在争议。肿瘤分期是最重要的预后因素。